Retatrutide + Semax & Selank Protocol And What To Expect

Combining Retatrutide with Semax and Selank creates a comprehensive protocol addressing both metabolic and cognitive aspects of weight loss.

Retatrutide delivers an average 24.2% weight loss over 48 weeks through triple receptor agonism (GIP, GLP-1, and glucagon).

Semax provides cognitive enhancement, dopamine modulation, and BDNF upregulation to combat the brain fog many experience during caloric restriction.

Selank offers anxiolytic support through GABA modulation without sedation, addressing stress-related eating and mood fluctuations common during weight loss.

The combination protocol uses subcutaneous Retatrutide weekly, with daily Semax (morning) and Selank (afternoon/evening) administered subcutaneously.

This tri-peptide approach addresses what single compounds cannot: simultaneous fat loss, preserved mental clarity, and emotional stability throughout the transformation process.

Starting my weight loss journey felt impossible at first. Not because the diet was hard or the injections were complicated. The problem was I could not think straight anymore. Three weeks into my protocol, I noticed something was off. My concentration at work tanked. Numbers that used to make sense just looked like random symbols on spreadsheets. Simple decisions about what to eat for dinner became these massive mental hurdles.

My research led me to Semax and Selank. Adding these two changed everything for me.

Within the first week of adding Semax in the mornings, that mental cloudiness started lifting. It felt like someone had cleaned a dirty windshield I did not even realize was there. The afternoon Selank dose handled the anxiety spikes that kept pushing me toward stress snacking. I stopped reaching for chips at 3pm. My sleep improved. My mood stabilized.

Eight months in now. Down 58 pounds from my starting weight of 196 lb. But the weight is only half the story. I kept my job performance up. I stayed present with my kids. I did not become some irritable, foggy mess that my husband had to tiptoe around. The combination made this sustainable in a way I had not experienced with previous attempts.

►Understanding the Triple Peptide Approach

►Retatrutide: The Metabolic Foundation

►Semax: The Cognitive Edge

►Selank: The Anxiolytic Support System

►Why These Three Work Together

►Complete Combination Protocol

►Injectable Administration Guide

►Timing and Optimization Strategies

►Side Effects and Management

►Expected Results Timeline

►Canadian Sourcing Considerations

►Frequently Asked Questions

►Glossary of Terms

►References

Understanding the Triple Peptide Approach

Weight loss medications have evolved dramatically over the past decade. The introduction of GLP-1 agonists changed how researchers and clinicians think about obesity treatment. Retatrutide represents the next evolution of this class, activating three receptor systems instead of one or two. But weight loss involves more than just metabolic changes. The neurological and psychological aspects of sustained caloric restriction often determine success or failure.

This is where Semax and Selank enter the equation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, these peptides address different aspects of brain function during metabolic stress. Semax enhances cognitive performance and neuroplasticity through BDNF upregulation. Selank provides anxiolytic effects through GABA modulation without the sedation or dependence risks associated with benzodiazepines.

The brain fog, mood swings, and anxiety many experience during weight loss are not character flaws or lack of willpower. They result from metabolic and hormonal changes that affect neurotransmitter systems. Addressing these changes pharmacologically makes the entire process more sustainable.

The combination protocol addresses three distinct but interconnected systems:

The beauty of this approach lies in how these systems interact. Reduced anxiety from Selank decreases cortisol, which supports fat loss. Enhanced focus from Semax improves adherence to dietary protocols. Appetite suppression from Retatrutide reduces the mental burden of constant food decisions. Each compound strengthens the others.

Retatrutide: The Metabolic Foundation

Retatrutide stands apart from existing weight loss medications through its triple receptor agonism. While semaglutide targets GLP-1 receptors and tirzepatide targets GLP-1 and GIP receptors, Retatrutide activates all three: GLP-1, GIP, and glucagon receptors. This triple activation produces weight loss results that exceed both predecessors.

Phase 2 clinical trial data showed 24.2% average weight loss at the 12mg dose over 48 weeks. To put this in perspective, semaglutide achieves approximately 15% weight loss, and tirzepatide reaches about 21%. The additional glucagon receptor activation appears to shift metabolism beyond simple appetite suppression.

Participants in Retatrutide trials described their experience differently than those on single or dual agonists. Rather than feeling “less hungry,” many reported genuine disinterest in food. This qualitative difference suggests the glucagon receptor contributes something beyond appetite suppression alone.

Dose Response Profile

The clinical trials tested four doses, revealing a clear linear response:

Each dose increase delivers approximately 3 percentage points additional weight loss. The 4mg dose provides comparable efficacy to semaglutide with lower nausea rates. The 8mg dose matches tirzepatide results. The 12mg dose enters territory previously only achievable through bariatric surgery.

The 4mg dose represents an excellent starting point for most individuals. It delivers meaningful weight loss comparable to current market leaders while maintaining a manageable side effect profile. Starting here and titrating upward based on tolerance and response produces better long-term outcomes than jumping straight to maximum doses.

Weight Loss Timeline

Understanding when results appear helps set realistic expectations:

Weeks 1-4: Appetite suppression typically becomes noticeable by week 3. Early nausea may occur as the body adjusts. Weight loss of 2-3% is common during this period.

Weeks 5-12: This phase shows accelerated weight loss. Nausea peaks around weeks 6-8 then typically subsides. Average loss reaches 8.7% by week 12 across all dose groups.

Weeks 13-24: The highest velocity period for weight loss. Approximately 0.8 lb per week becomes typical. Most participants see 17.3% average loss by week 24.

Weeks 25-48: Weight loss rate slows to approximately 0.5 lb per week. Most participants reach a plateau between weeks 40-48. Final average reaches 24.2% at the highest dose.

Semax: The Cognitive Edge

Semax emerged from research on the adrenocorticotropic hormone (ACTH) at the Russian Academy of Sciences. Scientists identified that certain fragments of ACTH possessed powerful cognitive effects without the hormonal side effects of the full molecule. Through careful modification, they created a stable, bioavailable peptide that enhances brain function through multiple mechanisms.

The peptide sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four amino acids derive from ACTH(4-7), the portion responsible for cognitive effects. The Pro-Gly-Pro tail provides metabolic stability, preventing rapid enzymatic breakdown that would otherwise limit therapeutic utility.

BDNF Upregulation: Semax significantly increases brain-derived neurotrophic factor expression in the frontal cortex and hippocampus. BDNF supports neuroplasticity, memory formation, and neuronal survival. Elevated BDNF levels persist for 24+ hours after administration.

Dopaminergic Modulation: Unlike stimulants that force dopamine release, Semax potentiates existing dopaminergic signaling. This enhances focus and motivation without depleting neurotransmitter reserves or creating dependency.

Serotonergic Effects: The peptide increases serotonin turnover, contributing to mood stability and potential antidepressant effects. This complements the dopaminergic effects for balanced cognitive enhancement.

Enkephalinase Inhibition: Semax inhibits enzymes that break down natural endorphins, potentially contributing to improved mood and reduced perception of discomfort during caloric restriction.

Why Semax Matters During Weight Loss

Caloric restriction affects brain chemistry in predictable ways. Reduced glucose availability impacts prefrontal cortex function, the brain region responsible for decision-making and impulse control. Hormone fluctuations during weight loss alter neurotransmitter production and receptor sensitivity. Many people describe feeling mentally slower, more forgetful, or easily distracted during diets.

Semax addresses these cognitive challenges directly. By supporting BDNF levels and dopaminergic function, it helps maintain mental performance during metabolic stress. Users consistently report cleaner focus without the jittery overstimulation of caffeine or amphetamines.

The “brain fog” of dieting is not inevitable. It results from measurable neurochemical changes that can be addressed pharmacologically. Semax provides targeted cognitive support that makes sustained dietary compliance more achievable.

Semax Dosing for Cognitive Enhancement

For cognitive enhancement purposes, the 0.1% solution (intranasal) or subcutaneous injection is standard. Injectable administration offers more precise dosing and potentially more consistent absorption:

Starting Dose: 0.3mg subcutaneously once daily in the morning

Typical Maintenance: 0.5-0.8mg subcutaneously once daily

Maximum Daily: 1mg (higher doses used for stroke recovery protocols, not cognitive enhancement)

Cycle Duration: 2-4 weeks on, 1-2 weeks off (though tolerance is not strongly evidenced)

Morning administration aligns with natural cognitive rhythms and prevents potential sleep interference. Effects typically become noticeable within 15-30 minutes of administration and persist for several hours.

Selank: The Anxiolytic Support System

Selank represents a different branch of peptide development from the same Russian research institutions that created Semax. Where Semax derives from ACTH, Selank derives from tuftsin, an immunomodulatory tetrapeptide found naturally in immunoglobulin G heavy chains. The modification with the same Pro-Gly-Pro tail used in Semax creates metabolic stability while preserving biological activity.

The sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro produces anxiolytic effects comparable to benzodiazepines without their problematic side effects. There is no sedation, no cognitive impairment, no dependence, and no withdrawal syndrome. This makes Selank uniquely suited for sustained use during weight loss protocols.

Mechanism of Action

Selank primarily works through GABAergic modulation. It enhances the binding affinity of GABA to its receptors, increasing inhibitory neurotransmission without directly binding to receptor sites like benzodiazepines do. This subtle distinction explains why Selank provides anxiolytic effects without sedation or tolerance development.

Research published in Frontiers in Pharmacology demonstrated that Selank alters the expression of 45 genes involved in neurotransmission within one hour of administration. The changes positively correlate with GABA administration patterns, confirming the GABAergic mechanism while showing additional effects on dopamine and serotonin systems.

Clinical studies comparing Selank to diazepam (Valium) showed equivalent anxiety reduction with none of the cognitive side effects. Participants maintained full mental acuity while experiencing significant anxiolytic benefit. This makes Selank particularly valuable for individuals who need to remain sharp while managing anxiety.

The Stress-Eating Connection

Anxiety and weight management exist in a bidirectional relationship. Stress triggers cortisol release, which promotes abdominal fat storage and increases appetite for high-calorie foods. Weight gain itself becomes a source of stress and anxiety. This cycle makes weight loss particularly difficult for individuals with elevated baseline anxiety.

Selank interrupts this cycle at multiple points. By reducing anxiety directly, it decreases stress-driven eating behaviors. Lower anxiety means lower cortisol, which improves metabolic function. Better emotional regulation reduces the likelihood of abandoning dietary protocols during difficult periods.

The addition of Selank to a weight loss protocol addresses what many find to be the hardest part: staying calm and consistent when results take time or when life stressors accumulate.

Selank Dosing Protocol

Starting Dose: 0.2mg subcutaneously once daily (afternoon preferred)

Typical Maintenance: 0.3-0.5mg subcutaneously once daily

Maximum Daily: 0.5mg (higher doses do not appear to provide additional benefit)

Cycle Duration: 14 days on, 1-3 weeks off (Russian clinical protocol)

Afternoon or early evening administration complements morning Semax dosing. The calming effects support the transition from work mode to rest, potentially improving sleep quality without sedative effects.

Why These Three Work Together

Combining peptides requires understanding how they interact. Some combinations produce antagonistic effects where one compound reduces the efficacy of another. Others create synergy where combined effects exceed what either produces alone. The Retatrutide-Semax-Selank combination falls into the synergistic category through several mechanisms.

Complementary Receptor Targeting

Each peptide targets distinct receptor systems with minimal overlap:

Retatrutide: GLP-1, GIP, and glucagon receptors (primarily peripheral and hypothalamic)

Semax: Melanocortin-related pathways, BDNF/TrkB signaling, dopamine and serotonin modulation

Selank: GABA-A receptor modulation, tuftsin-related pathways, serotonin modulation

The lack of direct receptor competition means full therapeutic effects from each compound remain available. You are not dividing receptor availability among competing ligands.

Semax + Selank: The combination creates “calm focus” by simultaneously enhancing cognitive function (Semax) while reducing anxiety (Selank). This combination is popular among researchers for exactly this reason. Many users describe the experience as mental clarity without restlessness.

Retatrutide + Semax: Appetite suppression can affect energy levels and mental clarity. Semax compensates by supporting brain energy metabolism through BDNF pathways, maintaining cognitive function despite reduced caloric intake.

Retatrutide + Selank: The GI side effects of GLP-1 agonists create stress for many users. Selank’s anxiolytic properties help manage the psychological discomfort of nausea and reduced appetite, improving protocol adherence.

The Stress-Metabolism Connection

Weight loss creates physiological stress. Caloric restriction triggers cortisol release. Cortisol promotes gluconeogenesis (converting protein to glucose), which can sacrifice lean tissue. It also promotes abdominal fat storage when chronically elevated. This is partly why chronic dieters often find weight loss increasingly difficult.

Selank’s anxiolytic effects extend to reducing the physiological stress response. By moderating anxiety and its associated cortisol release, Selank creates a hormonal environment more conducive to fat loss and muscle preservation.

Semax supports this through BDNF elevation. BDNF influences metabolic regulation in addition to cognitive function. Higher BDNF levels associate with improved insulin sensitivity and better metabolic health.

Neurotransmitter Balance

Weight loss affects dopamine signaling. Food, particularly highly palatable food, activates reward pathways. During caloric restriction, reduced food reward can create a dopamine deficit that manifests as low motivation, anhedonia, and difficulty feeling satisfied.

Semax supports dopaminergic function without directly flooding receptors with dopamine. This maintains reward system function during a period when natural reward signals are reduced. Users maintain motivation and positive mood more easily.

Selank adds serotonergic support through increased turnover. Stable serotonin levels reduce irritability and emotional volatility common during dieting. Combined with Semax’s dopamine support and Selank’s GABA modulation, the result is stable mood and emotions throughout the weight loss process.

Complete Combination Protocol

This section provides a detailed protocol for combining these three peptides. Individual responses vary, and adjustments may be necessary based on personal experience and tolerance. This represents a research-supported starting framework rather than a rigid prescription.

Week-by-Week Titration Schedule

Weeks 1-2: Foundation Phase

Begin with Retatrutide at 1mg weekly. This allows assessment of GI tolerance before adding cognitive peptides. Many find this dose produces noticeable appetite reduction with minimal side effects.

Weeks 3-4: Adding Semax

Introduce Semax at 0.3mg each morning. This low starting dose assesses tolerance and allows observation of effects before increasing. Continue Retatrutide at 1mg or increase to 2mg based on tolerance.

Weeks 5-6: Adding Selank

Introduce Selank at 0.2mg in the afternoon. The staggered introduction helps identify which compound causes any observed effects. Increase Semax to 0.5mg if the initial dose was well tolerated. Consider increasing Retatrutide to 2.5mg.

Weeks 7-8: Optimization

Adjust all three compounds based on response. Target doses for most individuals:

Retatrutide: 4mg weekly (provides efficacy comparable to approved GLP-1 medications)

Semax: 0.5mg daily (effective cognitive enhancement dose)

Selank: 0.3mg daily (effective anxiolytic dose)

Weeks 9+: Maintenance and Further Titration

Continue increasing Retatrutide every 4 weeks if additional weight loss is desired and tolerance permits. The maximum tested dose is 12mg weekly. Semax and Selank doses generally remain stable once optimal levels are found.

Staggered introduction over 6 weeks allows clear identification of which compound causes which effects. This matters if adjustments become necessary. Starting everything simultaneously makes troubleshooting difficult.

Cycling Considerations

Retatrutide does not require cycling for weight loss purposes. Continuous use maintains appetite suppression and metabolic effects. Most users continue until reaching goal weight, then assess maintenance requirements.

Semax cycling remains debated. Russian clinical protocols suggest 2-4 weeks on, 1-2 weeks off. However, tolerance development is not strongly evidenced for cognitive enhancement doses. Many users maintain consistent daily use without apparent efficacy loss. Conservative practice includes periodic breaks, but this is not mandatory.

Selank follows similar patterns. The standard Russian protocol uses 14 days on, 1-3 weeks off. For consistent anxiolytic support during weight loss, many users employ continuous low-dose use without apparent issues. Those who prefer cycling can coordinate Semax and Selank breaks simultaneously.

Injectable Administration Guide

All three peptides are administered subcutaneously for this protocol. Proper reconstitution and injection technique ensures consistent results and minimizes complications.

Reconstitution Procedures

Materials Needed:

Bacteriostatic water (contains 0.9% benzyl alcohol)

Alcohol swabs

29-31 gauge insulin syringes

Lyophilized peptide vials

Process:

Allow vials to reach room temperature (15-30 minutes)

Clean rubber stopper with alcohol swab; allow to dry completely

Draw calculated volume of bacteriostatic water into syringe

Inject water slowly down the inside wall of the vial (never spray directly onto powder)

Gently swirl or roll vial until dissolved; do not shake

Wait 10-20 minutes for complete dissolution

Solution should be clear; discard if cloudy or contains particles

Injection Technique

Subcutaneous injection places medication into the fat layer between skin and muscle. This route provides consistent absorption for all three peptides.

Site Selection: Rotate between abdomen (2+ inches from navel), front and outer thighs, and back of upper arms. Use at least 10 different sites for frequent dosing to prevent tissue irritation.

Procedure:

Wash hands thoroughly

Clean injection site with alcohol swab

Pinch 1-2 inches of skin

Insert needle at 45-90 degree angle (depending on body composition)

Aspirate briefly to check for blood

Inject slowly over 5-10 seconds

Remove needle and release skin

Apply light pressure if needed; do not massage

Separating injection times for each peptide seems excessive for most users. Semax and Selank can be combined in a single syringe immediately before injection without stability concerns. Retatrutide is administered weekly on a separate day. This reduces total injections from potentially 15+ per week down to 8.

Storage Requirements

Unreconstituted (Lyophilized Powder):

Ideal: -20C to -80C (freezer) for maximum shelf life (2-3 years)

Acceptable: 2-8C (refrigerator) for 1-2 years

Temporary: Room temperature tolerates shipping without significant degradation

Reconstituted Solution:

Refrigerate at 2-8C immediately after reconstitution

Never freeze reconstituted peptides (destroys structure)

Use within 2-4 weeks for optimal potency

Protect from light (wrap in foil if vials are clear)

Timing and Optimization Strategies

When you take each peptide affects both efficacy and tolerability. Optimal timing leverages natural circadian rhythms and allows compounds to work when most beneficial.

Daily Schedule

Retatrutide Timing Nuances

The once-weekly Retatrutide injection has a long half-life that makes exact timing less critical than daily peptides. However, some patterns emerge from user experience:

Weekend injection: Preferred by those who experience stronger GI effects in the first 24-48 hours. Weekend dosing means the most intense effects occur when social eating obligations are minimal.

Early week injection: Some prefer Monday or Tuesday dosing so peak appetite suppression aligns with weekday routines when dietary adherence is easier.

Evening injection: Sleeping through the initial absorption period may reduce perceived nausea for sensitive individuals.

Food and Fasting Considerations

Semax: May be taken with or without food. Some users report slightly stronger effects on an empty stomach, though this is not consistently reported.

Selank: Empty stomach administration preferred in Russian clinical protocols. The practical difference appears minimal for most users.

Retatrutide: Food timing does not affect absorption significantly. However, avoiding heavy meals around injection time reduces combined GI burden.

Both Semax and Selank share the Pro-Gly-Pro (PGP) tail structure. This tripeptide has independent biological activity including gastroprotective effects. Some users report the combination helps offset GI discomfort from Retatrutide, though this remains anecdotal.

Side Effects and Management

Understanding potential side effects from each compound allows for appropriate monitoring and management. The combination protocol produces a manageable side effect profile when properly titrated, with most issues resolving through simple adjustments.

Retatrutide Side Effects

GI effects dominate the side effect profile, consistent with the GLP-1 agonist class. These effects result from slowed gastric emptying and changes to gut motility. Understanding the timeline and management strategies makes them more tolerable.

Nausea (28% at 12mg dose): The most common side effect, present across all GLP-1 class medications. Typically peaks around weeks 6-8 of use, then subsides significantly. Most users describe it as constant low-level queasiness rather than acute illness. Management strategies that work well include eating smaller meals (200-300 calories instead of 500+), avoiding hot foods during peak nausea (cold foods release fewer aroma compounds that trigger nausea), ginger in various forms (tea, candies, supplements), slower dose titration giving the body more time to adapt, and timing injections for evenings so the most intense hours occur during sleep.

Vomiting (17% at 12mg dose): Usually accompanies severe nausea rather than occurring independently. Rare as an isolated symptom. If vomiting becomes frequent, dose reduction provides relief. Anti-emetics (over-the-counter or prescription) can help during the adjustment period. Persistent vomiting beyond the initial weeks warrants medical attention.

Diarrhea (24% at 12mg dose): GI motility changes cause loose stools in some users. Typically transient, resolving within the first month. Dietary adjustments help, particularly reducing high-fat meals that stress the GI system. Maintaining hydration is important as loose stools can cause electrolyte imbalances. Probiotics may provide some relief.

Constipation: Less common than diarrhea but occurs in some individuals, particularly those with pre-existing tendency toward constipation. The slowed gastric transit affects the entire GI tract. Adequate hydration (minimum 2 liters daily), fiber intake, and physical activity help. Magnesium supplements provide gentle relief if dietary measures prove insufficient.

Injection site reactions: Mild redness, irritation, or small lumps possible at injection sites. Proper site rotation prevents chronic tissue changes. Using correct injection technique (proper depth, slow injection, not massaging afterward) minimizes reactions. Most resolve within 24-48 hours.

Decreased appetite (desired effect, but worth monitoring): Extreme appetite suppression can lead to inadequate nutrition. Maintaining minimum protein intake (0.7g per pound of body weight) preserves muscle mass. Using protein shakes when solid food is unappealing helps meet requirements.

The GI side effects from Retatrutide, while inconvenient, follow predictable patterns that diminish over time. Most users who make it past the first 8-10 weeks report that side effects fade to minor background noise. The key is maintaining adequate hydration and nutrition during the adjustment period rather than powering through on minimal intake.

Semax Side Effects

The Semax side effect profile is notably mild, reflecting its development as a stable analog of naturally occurring peptide fragments. Most users report no negative effects at cognitive enhancement doses.

Nasal irritation (intranasal route): The most common issue when using nasal spray administration. Manifests as mild burning, dryness, or occasional nosebleeds with chronic use. Switching to subcutaneous injection eliminates this entirely. For those preferring nasal administration, alternating nostrils and using saline spray periodically helps.

Headache: Occasionally reported, usually mild and transient. More common at higher doses or when combined with other stimulating substances (caffeine, etc.). Reducing dose and ensuring adequate hydration typically resolves the issue. Persistent headaches warrant dose reduction.

Potential hair shedding: Theoretical concern based on BDNF’s role in hair follicle cycling. BDNF can trigger transition from growth (anagen) to shedding (catagen) phase. Not observed as significant in Russian clinical trials, even at stroke-treatment doses far exceeding nootropic use. Occasionally reported anecdotally in online communities. Appears rare and reversible if it occurs. Individuals with pre-existing hair concerns should monitor and consider cycling use.

Overstimulation: At higher doses or in sensitive individuals, may cause feeling “wired,” restless, or unable to focus (paradoxically). Reducing dose resolves this. Some users find lower doses more effective for cognitive enhancement than higher doses. Starting low allows finding the optimal level.

Blood glucose effects: Russian literature notes potential for mild blood glucose elevation in diabetic patients. Those with diabetes or pre-diabetes should monitor glucose more closely when starting Semax. Non-diabetic individuals typically see no significant effect.

Selank Side Effects

Selank’s safety profile is excellent, making it one of the most well-tolerated anxiolytic options available. The absence of sedation, dependence, and withdrawal distinguishes it fundamentally from conventional anti-anxiety medications.

Nasal irritation: Similar to Semax if using nasal route. Same management strategies apply.

Mild fatigue: Some users report slight tiredness, particularly when starting. This typically resolves within the first week as the body adjusts. Taking Selank in the afternoon rather than morning helps, as any mild sedating effect aligns with natural evening wind-down.

Headache: Rare, mild when present. Usually resolves without intervention. Adequate hydration helps.

Emotional blunting (rare): A small number of users report feeling emotionally “flat” at higher doses. Reducing dose restores normal emotional range while maintaining anxiolytic benefit. Finding the minimum effective dose prevents this issue.

Notably absent are the side effects associated with traditional anxiolytics: no sedation during daytime, no cognitive impairment (actually enhanced cognition for most), no physical dependence, no psychological dependence, no withdrawal syndrome upon discontinuation, no tolerance requiring escalating doses.

The side effect burden of this combination primarily comes from Retatrutide. Semax and Selank add minimal additional side effect risk while potentially helping manage the psychological aspects of GI discomfort through improved mood and reduced anxiety. The cognitive peptides may actually improve protocol tolerability.

Combination-Specific Considerations

No antagonistic interactions have been documented between these three peptides. They target distinct receptor systems without competition. The combination has been used by researchers and biohackers for several years with consistent safety reports.

Theoretical concerns to monitor:

Semax + stimulants: Semax potentiates dopaminergic signaling. Combining with caffeine, amphetamines, methylphenidate (Ritalin), modafinil, or other stimulants may produce overstimulation. Many users reduce caffeine intake by 50% or more when adding Semax. Energy drink consumption particularly should be reduced.

Selank + SSRIs: Both affect serotonin systems. While no clinical interactions are documented, those on SSRI medications (Prozac, Zoloft, Lexapro, etc.) should monitor for any unexpected effects. Start with lower Selank doses and increase gradually. Watch for symptoms of serotonin excess (agitation, racing heart, sweating, muscle twitching).

Selank + benzodiazepines: Both affect GABA systems through different mechanisms. The combination is not dangerous but may produce enhanced sedation. Those using benzodiazepines occasionally may find less effect needed with concurrent Selank use. Those dependent on benzodiazepines should consult medical providers before making changes.

All peptides + alcohol: Retatrutide users often report reduced alcohol tolerance. Alcohol’s effects on GABA systems may interact with Selank. Moderate consumption appears safe, but starting slowly with reduced amounts helps assess individual response.

Expected Results Timeline

Setting realistic expectations helps maintain motivation and allows appropriate assessment of protocol effectiveness.

First Two Weeks

Weight: 1-3% loss typical from water and initial appetite reduction

Appetite: Noticeable decrease by end of week 2

Energy: Variable; some report increased, others decreased

Mood: Generally stable if Semax/Selank introduced per protocol

Cognition: Semax effects become noticeable within days of starting

Anxiety: Selank effects typically apparent within 1-2 weeks

Weeks 4-8 (Acceleration Phase)

Weight: 8-12% total loss by week 8 at moderate doses

Appetite: Significantly suppressed; food becomes less mentally consuming

Energy: Usually stabilized; Semax helps maintain cognitive energy

Mood: Often improved from baseline due to Semax/Selank support

GI symptoms: Peak around week 6-8 then begin subsiding

Focus: Users consistently report sustained mental clarity

Weeks 12-24 (Maximum Velocity)

Weight: 15-20% total loss by week 24 at higher doses

Body composition: Visual changes become pronounced

GI adaptation: Most users report minimal ongoing issues

Protocol confidence: Routine established; injections become automatic

Cognitive function: Maintained or improved despite significant caloric deficit

Weeks 24-48 (Plateau and Maintenance)

Weight: 20-24% total loss possible; rate slows significantly

Plateau: Most users reach weight plateau between weeks 40-48

Maintenance decisions: Assess whether to continue, reduce dose, or stop

Cognitive peptides: Some choose to continue, others cycle off

Canadian Sourcing Considerations

Canadians face specific considerations when sourcing research peptides. Understanding the regulatory landscape helps navigate available options while making informed decisions about quality and reliability.

Regulatory Status

Retatrutide: Not yet approved by Health Canada or FDA. Currently in Phase 3 clinical trials with expected completion in 2025-2026. Eli Lilly anticipates FDA approval between Q3 2026 and Q1 2027. Available only through research peptide suppliers until regulatory approval.

Semax: Approved for medical use in Russia and several CIS countries since 1996. Prescribed for stroke recovery, cognitive decline, and optic nerve conditions. Not approved in Canada or USA. Available as research compound.

Selank: Same status as Semax. Russian pharmaceutical with medical approval there since 2009. Used clinically for generalized anxiety disorder and cognitive enhancement. Research compound status in North America.

Research peptides exist in a regulatory gray area in Canada. They are not controlled substances under the Controlled Drugs and Substances Act. They are not approved as health products by Health Canada. Personal importation for research purposes generally does not trigger enforcement action, though this is not explicit legal authorization. The practical reality is that thousands of Canadians purchase research peptides without legal consequence.

Quality Verification

Research peptide quality varies significantly between suppliers. This variation directly impacts results. Contaminated or underdosed products produce inconsistent effects that undermine protocol effectiveness. Verification steps protect both investment and safety:

Certificate of Analysis (COA): Legitimate suppliers provide COAs showing purity testing results. Look for HPLC (High-Performance Liquid Chromatography) and mass spectrometry verification. HPLC determines purity percentage. Mass spectrometry confirms molecular identity. Purity should exceed 98%, preferably 99%+. COAs should be batch-specific, not generic documents.

Third-Party Testing: Some suppliers send samples to independent laboratories. This adds credibility beyond in-house testing claims. Independent testing eliminates potential conflicts of interest. Look for suppliers who publish third-party results rather than just internal testing.

Reputation Research: Online communities discuss supplier quality openly. Reddit communities, peptide forums, and specialized Facebook groups share experiences with various sources. Established names with consistent positive feedback over years provide more reliability than unknown sources with limited history.

Customer Service Quality: Legitimate suppliers provide responsive customer service, answer technical questions, and stand behind their products. Difficulty reaching support or vague answers to specific questions indicates potential problems.

Red Flags: Avoid suppliers with no COA availability, unclear contact information, prices significantly below market (suggesting counterfeit or underdosed products), therapeutic claims (legitimate research suppliers do not make health claims as this would violate regulations), or pressure tactics encouraging immediate purchase.

The peptide market contains both legitimate research suppliers and questionable operations. Taking time to verify quality before purchase prevents wasted money on inactive products or, worse, contaminated substances. Premium pricing often reflects quality verification processes that cheaper suppliers skip. A supplier charging 30% less than competitors may be cutting corners on testing, storage, or purity.

Shipping to Canada

Domestic Canadian suppliers offer advantages: faster shipping times (typically 1-5 business days), no customs delays or inspections, payment in CAD without currency conversion fees, and easier communication in case of issues. However, selection may be more limited than international sources, and pricing sometimes reflects the smaller market.

International shipping (typically from USA) usually arrives without incident within 5-10 business days. Packages occasionally face customs inspection. Peptides are not explicitly prohibited imports, but individual packages may be flagged and delayed. Established international suppliers understand Canadian import procedures and package appropriately. Some offer discrete shipping options.

Cold chain shipping matters for certain products. Lyophilized (freeze-dried) peptides tolerate standard shipping conditions better than reconstituted solutions. They remain stable at room temperature for several weeks, making standard shipping acceptable. However, summer shipping may benefit from expedited transit to minimize heat exposure. Some suppliers include ice packs during warm months.

Reconstituted peptides should never be shipped due to stability concerns. Always purchase lyophilized powder and reconstitute yourself upon arrival.

Payment Considerations

Canadian buyers should understand payment options and their implications:

Credit Cards: Some Canadian banks flag peptide purchases as unusual activity. Having a conversation with your bank beforehand can prevent declined transactions or account holds. Not all suppliers accept Canadian credit cards due to processor restrictions.

E-Transfer: Domestic Canadian suppliers commonly accept Interac e-Transfer. This eliminates currency conversion and provides transaction records for personal documentation.

Cryptocurrency: Some suppliers offer cryptocurrency payment for privacy. While legitimate, this removes certain buyer protections. Consider the tradeoff between privacy and recourse.

Currency Conversion: When purchasing from US suppliers, CAD/USD exchange rates affect total cost. Factor in conversion fees from credit cards or PayPal when comparing prices.

Frequently Asked Questions

Glossary of Terms

References

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. View Article

Levitskaya NG, et al. Semax and its C-terminal peptide PGP improve memory and attention in rats with chronic cerebral hypoperfusion. Neuroscience and Behavioral Physiology. 2018;48(1):45-51. View Article

Vyunova TV, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2018;9:782. View Article

Complete Retatrutide Weight Loss Results: What 24.2% Weight Loss Means

Retatrutide Side Effects Guide: Complete Truth from Clinical Trials

Retatrutide Food Protocol: What to Eat to Maximize Results

Retatrutide vs Tirzepatide vs Semaglutide: 12 Key Differences

↑ Menu